Epigenetic Modulation in Glioblastoma Therapy

Epigenetic modulation encompasses reversible alterations to the chromatin landscape that regulate gene expression without changing the underlying DNA sequence. In glioblastoma, a highly aggressive primary brain tumour, these modifications include DNA methylation, histone post-translational changes and non-coding RNA interference. Aberrant DNA methylation patterns, such as hypermethylation of tumour suppressor promoters, and dysregulated histone acetylation or methylation contribute to unchecked proliferation, invasiveness and therapeutic resistance. Mutations in genes encoding epigenetic regulators – notably isocitrate dehydrogenase (IDH1/2), histone H3 variants and various methyltransferases or demethylases – underlie characteristic methylomes and histone modification profiles in distinct glioblastoma subgroups. Therapeutic strategies exploit the reversibility of these marks, employing histone deacetylase inhibitors, DNA methyltransferase inhibitors and small molecules targeting histone-modifying enzymes to re-activate silenced genes, impair cancer stem cell self-renewal and remodel the tumour microenvironment. Recent advances have also explored synergistic combinations with immunotherapy and anti-angiogenic agents, underscoring the global significance of epigenetic interventions in overcoming the formidable clinical challenges posed by glioblastoma.

Research from Nature Portfolio

Recent studies have elucidated the central role of specific histone deacetylases in sustaining glioblastoma stem-like populations. Detailed functional analyses identify HDAC2 as a pivotal regulator of chromatin accessibility in brain tumour stem cells, where it forms a complex with SMAD3 and the SKI oncoprotein. Disruption of the HDAC2-SMAD3-SKI axis impairs self-renewal, diminishes tumourigenic potential in orthotopic models and heightens sensitivity to differentiation cues. These findings not only clarify the mechanistic basis for selective HDAC2 targeting but also establish a rationale for tailored epigenetic therapies aimed at eradicating resistant stem-like compartments in glioblastoma.

Epigenetic Modulation in Glioblastoma Therapy publication trend

The graph below shows the total number of articles in epigenetic modulation in glioblastoma therapy across all publications each year (not limited to Nature Index journals).

Technical terms

DNA methylation: Covalent addition of methyl groups to cytosine bases in DNA, often resulting in transcriptional repression.

Histone acetylation: Attachment of acetyl groups to lysine residues on histone tails, usually associated with open chromatin and active transcription.

Histone deacetylase (HDAC): Enzyme that removes acetyl groups from histones, promoting chromatin compaction and gene silencing.

Chromatin accessibility: Degree to which DNA is exposed to transcriptional machinery, governed by nucleosome positioning and histone modifications.

Non-coding RNA: RNA molecules that do not encode proteins but regulate gene expression through chromatin modulation, mRNA stability or translation control.

References

1. Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics. Nature Communications (2023).
2. Impact of epigenetic reprogramming on antitumor immune responses in glioma. Journal of Clinical Investigation (2023).
3. Epigenetic Mechanisms Histone Deacetylase–Dependent Regulate the Glioblastoma Angiogenic Matrisome and Disrupt Endothelial Cell Behavior In Vitro. Molecular & Cellular Proteomics (2024).
4. The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development. International Journal of Molecular Sciences (2023).